Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
The 3-dose oral pentavalent RV vaccine (RotaTeq™), consisting of serotypes G1, G2, G3, G4 and P1A[8], was licensed in the USA in 2006. The first dose should be administered between the ages of 6 ...
The oral human-bovine pentavalent reassortant RV vaccine (RotaTeq™) consists of five human-bovine reassortants suspended in a fully liquid buffer-stabilized formulation. The vaccine is based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback